Comparative Pharmacology
Head-to-head clinical analysis: ANAPROX DS versus VIVLODEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANAPROX DS versus VIVLODEX.
ANAPROX DS vs VIVLODEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
COX-2 inhibitor; reduces prostaglandin synthesis via inhibition of cyclooxygenase-2 (COX-2) with minimal COX-1 inhibition.
550 mg orally every 8 to 12 hours; maximum 1375 mg/day.
Once daily oral administration of 100 mg or 200 mg capsules. The recommended dose is 100 mg once daily; dose may be increased to 200 mg once daily if response is inadequate. Maximum daily dose: 200 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 12–17 hours (mean ~14 hours), allowing twice-daily dosing. Steady-state is achieved after 4–5 doses.
Terminal elimination half-life of the active moiety meloxicam is approximately 20 hours (range 12-24 h), allowing once-daily dosing in chronic pain.
Renal elimination of naproxen and its metabolites accounts for approximately 95% of the dose, with about 60% as unchanged drug and 40% as conjugated or hydroxylated metabolites. Biliary/fecal excretion is negligible (<5%).
VIVLODEX is a meloxicam NSAID prodrug. Following hydrolysis to meloxicam, excretion is primarily hepatic (metabolism) and renal (urine). Approximately 50% of meloxicam dose is excreted in urine as metabolites and <5% as parent drug; about 40% in feces. Biliary excretion is minor.
Category C
Category C
NSAID
NSAID